Who we are
LIFEFACTORS WAS BORN TO ENSURE ACCESS TO ESSENTIAL MEDICATIONS FOR THE TREATMENT OF RARE AND HIGH COST DISEASES
Since 2017, after acquiring the Dual-Phase Aqueous Separation System (SDFA for its acronym in Spanish) patented technology, we have built a series of solutions to support governments and healthcare systems in the implementation of this technology in their territories granting them the autonomy to produce and distribute blood derived products.
2017
Beginning of the technology transfer
2019
Construction of the Scale A Manufacturing Plant. Scaling up processes. GMP request. First contracts.
2021
Latam regulatory processes.
2023
International expansion.
2018
Foundation of LifeFactors.
2020
Design and feasibility of the Scale I Manufacturing Plant.
2022
GMP process. Scale A Manufacturing Plant. Beginning of the construction of the Scale I Manufacturing Plant.
2024
Operations of the Scale I Manufacturing Plant. Commercial product launch.
2017
Beginning of the technology transfer
2018
Foundation of LifeFactors.
2019
Construction of the Scale A Manufacturing Plant. Scaling up processes. GMP request. First contracts.
2020
Design and feasibility of the Scale I Manufacturing Plant.
2021
Latam regulatory processes.
2022
GMP process. Scale A Manufacturing Plant. Beginning of the construction of the Scale I Manufacturing Plant.
2023
International expansion.
2024
Operations of the Scale I Manufacturing Plant. Commercial product launch.
IMPROVING THE NATIONAL BLOOD SYSTEM
IMPLEMENTING A DISRUPTIVE AND INNOVATIVE TECHNOLOGY THAT SURPASSES THE CURRENT PRODUCTIVITY LEVELS
ADVANCING IN THE BLOOD DERIVED PRODUCT SELF-SUFICIENCY
Global Solutions
OBJECTIVE:
As our greatest commitment
is to life, we are committed
to innovating with health biosolutions that have a global reach.
Objetctive
We contribute
to the accelerated
GROWTH
Of the demand
With an
EXCHANGE VALUE
model
Technology that
PROMOTES
self-sufficiency
We enable and
FACILATE
the plasma process
We implement mutual
IMPROVEMENT
actions
We REDUCE
shortage and high
production costs
Innovation in the ecosystem
A modular pharmaceutical industrialization model to produce blood derived products, under the main international quality standards (incremental capacities of 50 - 300 thousand liters of plasma each year).
A system for converting discarded recovered plasma, today incinerated, into pharmaceutical raw material. It is estimated that LATAM has more than 1.7 million liters of unused plasma in the blood transfusion system.
Insertion in modern models of drug marketing and comprehensive patient care in pathologies such as:
immunology, haemato-oncology, hemophilia, neurological, among others. All of them of high cost and more complex for the health systems of the countries.
Internal knowledge networks with an ecosystem specialized in biopharmaceutical policies and regulations, clinical research, bioengineering and the development of biological medicinal products.
Better
yield
MORE AVAILABILITY of blood
derived products per LITRE OF PROCESSED PLASMA.
INCREASE in EFFICIENCY
in production costs.
QUALITY, SAFETY AND EFFICACY
of biological medicinal products, according to the European Pharmacopeia standards
COMPLIANCE with INTERNATIONAL QUALITY STANDARDS, based on Good Pharmaceutical Manufacturing Practices
Shared value
Bio-
solutions
LIFEFACTORS SUPPORTS COUNTRIES WITH TECHNOLOGIES
THAT ALLOW THEM TO IMPROVE THE QUALITY AND QUANTITY
CONDITIONS OF THEIR PLASMA TO OBTAIN AN INDUSTRIAL USE THUS
PROVIDING THE NECESSARY BIOLOGICAL MEDICINAL PRODUCTS
FOR THEIR PATIENTS.
Therapeutic approach
Once acknowledging the benefits of blood derived products, their demand has
increased in recent years due to their contribution to more than 200 clinical conditions.
This is why in LifeFactors we focus on efficient biosolutions and innovative production
technology to positively contribute to humanity.
Blood derived
products
